Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis

The Pharmacogenomics Journal volume 21, pages 200–215 (2021)Cite this article

Subjects

Abstract

The correlations between hydroxytryptamine receptor 2A (HTR2A) gene polymorphisms (1438A/G, 102T/C, and rs7997012G/A) and the safety and efficacy of antidepressants in depression patients were constantly reported, but conclusions are debatable. This meta-analysis ascertained forty-two studies on the efficacy (including response and remission) and side-effect issued before February 2020. Pooled analyses indicated significant associations of 1438A/G polymorphism (16 studies, 1931 subjects) and higher response within dominant model (OR: 1.40, 95% CI: 1.12–1.76); rs7997012G/A polymorphism (nine studies, 1434 subjects) and higher remission in overall models (dominant model: OR: 1.30, 95% CI: 1.01–1.66; recessive model: OR: 2.20, 95% CI: 1.53–3.16; homozygote model: OR: 2.73, 95% CI: 1.78–4.17); 102T/C polymorphism (eight studies, 804 subjects) and reduced risk of side-effect within recessive (OR: 0.57, 95% CI: 0.4–0.83) and homozygote models (OR: 0.54, 95% CI: 0.29–0.99). For depression patients, genotyping of HTR2A polymorphisms is a promising tool for estimating the outcome and side-effect of antidepressants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2: Forest plots for the association between HTR2A 1438A/G polymorphisms and the response of ADs in the treatment of depression in dominant genetic model.
Fig. 3: Forest plots for the association between HTR2A 102T/C polymorphisms and the side effects of ADs in the treatment of depression in recessive genetic model and homozygote genetic model.
Fig. 4: Forest plots for the association between HTR2A rs7997012 polymorphisms and the remission of ADs in the treatment of depression in three genetic models Box size represents study weighting.
Fig. 5

Similar content being viewed by others

References

  1. World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization. 2017.

  2. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Xu Y, Wei H, Zhu Y, Zhu Y, Zhang N, Qin J, et al. Potential serum biomarkers for the prediction of the efficacy of escitalopram for treating depression. J Affect Disord. 2019;250:307–12.

    CAS  PubMed  Google Scholar 

  4. Brunoni AR, Padberg F, Vieira ELM, Teixeira AL, Carvalho AF, Lotufo PA, et al. Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:211–7.

    CAS  PubMed  Google Scholar 

  5. Fabbri C, Hosak L, Mossner R, Giegling I, Mandelli L, Bellivier F, et al. Consensus paper of the WFSBP Task Force on Genetics: genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World J Biol Psychiatry. 2017;18:5–28.

    PubMed  Google Scholar 

  6. Lam YWF, Scott SA. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Second Edition ed: Elsevier Inc.; 2019. p. 191–3.

  7. Calabro M, Mandelli L, Crisafulli C, Lee SJ, Jun TY, Wang SM, et al. Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: focus on Treatment Outcomes in an Asiatic Sample. Adv Ther. 2018;35:1656–70.

    PubMed  PubMed Central  Google Scholar 

  8. Fabbri C, Serretti A. Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep. 2015;17:50.

  9. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, et al. The Effect of Paroxetine on 5-HT2A Receptors in Depression: an [18F] Setoperone PET Imaging Study. Am J Psychiatry 2001;158:78–85.

    CAS  PubMed  Google Scholar 

  10. Chen K, Yang WU, Grimsby J, Shih JC. The human 5-HT 2 receptor is encoded by a multiple intron-exon gene. Mol Brain Res. 1992;14:20–6.

    CAS  PubMed  Google Scholar 

  11. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15:473–500.

    CAS  PubMed  Google Scholar 

  12. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:183–94.

    CAS  PubMed  Google Scholar 

  13. Lin JY, Jiang MY, Kan ZM, Chu Y. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2014;168:430–8.

    CAS  PubMed  Google Scholar 

  14. Yu Y. Association study of 5-HT2A receptor, NET, FKBP5 gene polymorphisms with major depressive disorder and antidepressants treatment response. Changsha: Central South University; 2009.

  15. Higuchi H, Takahashi H, Kamata M, Yoshida K. Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression. Neuropsychiatr Dis Treat. 2009;5:393–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Murata Y, Kobayashi D, Imuta N, Haraguchi K, Ieiri I, Nishimura R, et al. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010;30:11–7.

    CAS  PubMed  Google Scholar 

  17. Masiran R, Sidi H, Mohamed Z, Mohamed Saini S, Nik Jaafar NR. Association between 5HT2A polymorphism and selective serotonin reuptake inhibitor (SSRI)-induced sexual desire disorder (SDD) among Malaysian women. Asia-Pac Psychiatry. 2013;5:41–9.

    PubMed  Google Scholar 

  18. Masiran R, Sidi H, Mohamed Z, Mohd, Nazree NE, Nik Jaafar NR, et al. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms. J Sex Med. 2014;11:1047–55.

    CAS  PubMed  Google Scholar 

  19. Demirbugen OzM, Uckun Z, Yuce-Artun N, Baskak B, Ozdemir H, Kizil Ozel T, et al. The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients. Hum Psychopharmacol. 2018;33:e2673.

    Google Scholar 

  20. Poweleit EA, Aldrich SL, Martin LJ, Hahn D, Strawn JR, Ramsey LB. Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders. J Child Adolesc Psychopharmacol. 2019;29:348–61.

    CAS  PubMed  Google Scholar 

  21. Amitai M, Kronenberg S, Carmel M, Michaelovsky E, Frisch A, Brent D, et al. Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders. J Neural Transm (Vienna). 2016;123:1347–54.

    CAS  PubMed  Google Scholar 

  22. Oz MD, Baskak B, Uckun Z, Artun NY, Ozdemir H, Ozel TK, et al. Association between serotonin 2A receptor (HTR2A), serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients. Pharmacogenomics J. 2020;20:443–50.

  23. Liang CS, Ho PS, Chiang KT, Su HC. 5-HT2A Receptor-1438 G/A Polymorphism and Serotonergic Antidepressant-Induced Sexual Dysfunction in Male Patients with Major Depressive Disorder: A Prospective Exploratory Study. J Sex Med. 2012;9:2009–16.

    CAS  PubMed  Google Scholar 

  24. Yuan R, Yuan F, Ren D, Zhu Y, Bi Y, Hu J, et al. HTR1A and HTR2A variants may not predict venlafaxine treatment response in China Han population with major depressive disorder. Psychiatry Res. 2018;270:1179–80.

    CAS  PubMed  Google Scholar 

  25. Siriguleng LiuX, Yang F, Yang H. Study on the Association of 5-HTR1A/2A Receptor Gene Polymorphism with Antidepressant Efficacy of SSRIs. China Pharm. 2018;29:2394–8.

    Google Scholar 

  26. Gasso P, Blazquez A, Rodriguez N, Boloc D, Torres T, Mas S, et al. Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: impact of the HTR2A rs7997012 Polymorphism. J Child Adolesc Psychopharmacol. 2018;28:711–8.

    CAS  PubMed  Google Scholar 

  27. Ochi T, Vyalova NM, Losenkov IS, Paderina DZ, Pozhidaev IV, Loonen AJM, et al. Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression. Front Pharmacol. 2019;10:1462

  28. Mikhalitskaya E, Vyalova N, Losenkov I, Simutkin G, Ivanova S, Bokhan N. Assessment of association of polymorphic variants of serotoninergic system genes with depressive symptoms, clinical remission and response to antidepressant therapy. Eur Neuropsychopharmacol. 2019;29:S230–S1.

    Google Scholar 

  29. Brunoni AR, Carracedo A, Amigo OM, Pellicer AL, Talib L, Carvalho AF, et al. Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial. Braz J Psychiatry. 2020;42:128–35.

  30. Blazquez Hinojosa A, Gassó P, Rodríguez N, Boloc D, Torres T, Mas S, et al. Relationship between remission and recovery from a depressive episode and 5HTR2A gene polymorphisms in a child and adolescent sample. Eur Neuropsychopharmacol. 2019;29:S334–S5.

    Google Scholar 

  31. Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H, et al. Association between-1438G/A promoter polymorphism in the 5-HT2A receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002;46:136–40.

    CAS  PubMed  Google Scholar 

  32. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161:1575–80.

    PubMed  Google Scholar 

  33. Choi MJ, Kang RH, Ham BJ, Jeong HY, Lee MS. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology. 2005;52:155–62.

    CAS  PubMed  Google Scholar 

  34. Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006;53:186–95.

    CAS  PubMed  Google Scholar 

  35. Wu C, Yue W, Mi W, Zhang R, Du B, Tan Y, et al. Study on the relationship between serotonin receptor 2A gene polymorphism and clinical response to paroxetine. Chin J C lin Pharmacol. 2010;26:577–80.

    CAS  Google Scholar 

  36. Zhu Y, Ying Z, Ma H. 5-HTR2A Gene-1438A/G Polymorphism and Effect of Fluoxetine in Major Depressive Disorder Patients. Chin Gen Pract. 2010;13:1431–4.

    CAS  Google Scholar 

  37. Liu W, Zhang L, Yin H, Luo J. Association study of 5-HTR2A promoter region gene polymorphisms with unipolar depression and paroxetine treatment response in northwest Chinese Han population. Chin J Behav Med Brain Sci. 2011;20:704–6.

    CAS  Google Scholar 

  38. Arias B, Fabbri C, Gressier F, Serretti A, Mitjans M, Gasto C, et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology 2013;67:41–7.

    CAS  PubMed  Google Scholar 

  39. Yang D, Zhao J, Yu Y, Wu R. Association Study of 5-HT2A Receptor Gene Polymorphisms with Antidepressants Treatment Response. Chin J Clin Psychol. 2013;21:51–3.

    CAS  Google Scholar 

  40. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R, et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol. 2002;5:27–35.

    CAS  PubMed  Google Scholar 

  41. Hong CJ, Chen TJ, Yu YWY, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006;6:27–33.

    CAS  PubMed  Google Scholar 

  42. Lin E, Chen PS, Chang HH, Gean PW, Tsai HC, Yang YK, et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1167–72.

    CAS  PubMed  Google Scholar 

  43. Wilkie MJV, Smith G, Day RK, Matthews K, Smith D, Blackwood D, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 2009;9:61–70.

    CAS  PubMed  Google Scholar 

  44. Chen J, Ge X, Huang J, Wu Y, Zhu Z. Study on the association between 5-HTR2A gene polymorphisms and the effect of xiaoyaosan in the treatment of first-episode depression. Guangzhou Med J. 2016;47:81–3.

    Google Scholar 

  45. Qesseveur G, Petit AC, Nguyen HT, Dahan L, Colle R, Rotenberg S, et al. Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. Neuropharmacology 2016;105:142–53.

    CAS  PubMed  Google Scholar 

  46. Bukh JD, Bock C, Vinberg M, Werge T, Gether U, Kessing LV. No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment. Eur Neuropsychopharmacol. 2010;20:327–35.

    CAS  PubMed  Google Scholar 

  47. Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Muller-Myhsok B, et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol. 2010;20:65–8.

    CAS  PubMed  Google Scholar 

  48. Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, et al. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol. 2010;25:228–31.

    PubMed  Google Scholar 

  49. Serretti A, Fabbri C, Pellegrini S, Porcelli S, Politi P, Bellino S, et al. No Effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. Psychiatry Investig. 2013;10:180–9.

    PubMed  PubMed Central  Google Scholar 

  50. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010;35:727–40.

    CAS  PubMed  Google Scholar 

  51. Basu A, Chadda RK, Sood M, Kaur H, Kukreti R. Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study. Indian J Med Res. 2015;142:40–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Dong ZQ, Li XR, He L, He G, Yu T, Sun XL. 5-HTR1A and 5-HTR2A genetic polymorphisms and SSRI antidepressant response in depressive Chinese patients. Neuropsychiatr Dis Treat. 2016;12:1623–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Viikki M, Huuhka K, Leinonen E, Illi A, Setala-Soikkeli E, Huuhka M, et al. Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neurosci Lett. 2011;501:20–4.

    CAS  PubMed  Google Scholar 

  54. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009;20:1125–8.

    CAS  PubMed  Google Scholar 

  55. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, et al. HTR2A is Associated with SSRI Response in Major Depressive Disorder in a Japanese Cohort. Neuromolecular Med. 2010;12:237–42.

    CAS  PubMed  Google Scholar 

  56. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, et al. Monoamine oxidase a gene polymorphism, 5-HT2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 2003;48:10–3.

    CAS  PubMed  Google Scholar 

  57. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006;31:2281–8.

    CAS  PubMed  Google Scholar 

  58. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006;31:825–31.

    CAS  PubMed  Google Scholar 

  59. Murphy GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry. 2003;160:5.

    Google Scholar 

  60. Tanaka M, Kobayashi D, Murakami Y, Ozaki N, Suzuki T, Iwata N, et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol. 2008;11:261–7.

    CAS  PubMed  Google Scholar 

  61. Kang RH, Choi MJ, Paik JW, Hahn SW, Lee MS. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int J Psychiatry Med. 2007;37:315–29.

    PubMed  Google Scholar 

  62. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, et al. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol. 2012;26:349–59.

    CAS  PubMed  Google Scholar 

  64. Badamasi IM, Lye MS, Ibrahim N, Ling KH, Stanslas J. Association between polymorphism of genes encoding for 5-HT1A and 5-HT2A receptors and response to selective serotonin reuptake inhibitors in malaysian patients with major depressive disorder. FASEB J. 2017; 31. Suppl 1: 773.

  65. Li HF, Yu X, Yang K, He CY, Kou SJ, Cao SX, et al. The relationship between single nucleotide polymorphisms in 5-HT2A signal transduction-related genes and the response efficacy to selective serotonin reuptake inhibitor treatments in Chinese patients with major depressive disorder. Genet Test Mol Biomark. 2012;16:667–71.

    CAS  Google Scholar 

  66. Kang HJ, Bae KY, Kim SW, Shin IS, Hong YJ, Ahn Y, et al. Associations between Serotonergic Genes and Escitalopram Treatment Responses in Patients with Depressive Disorder and Acute Coronary Syndrome: the EsDEPACS Study. Psychiatry Investig. 2016;13:157–60.

    CAS  PubMed  Google Scholar 

  67. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genom. 2009;19:1–10.

    CAS  Google Scholar 

  68. Su YA, Li JT, Dai WJ, Liao XM, Dong LC, Lu TL, et al. Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment. Int Clin Psychopharmacol. 2016;31:127–33.

    PubMed  Google Scholar 

  69. Rajewska-Rager A, Dmitrzak-Weglarz M, Kapelski P, Skibińska M, Kaczmarkiewicz-Fass M, Hauser J. Association between polymorphisms of ins/del in the 5-HTT gene and T102C in the 5HTR2A gene and the drug response for escitalopram and nortriptyline in depressed patients. Psychiatr Pol. 2008;42:903–14.

    PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by grants from the National Natural Science Foundation of China (Grants 81403012) and the Fundamental Research Funds of Union Hospital (No:02032017-285). The study has been registered on PROSPERO. The registration number was: CRD42019143047.

Author information

Author notes

  1. These authors contributed equally: Yuan-sheng Wan, Xue-jia Zhai

  2. These authors contributed equally: You-sheng Ai, Li-bo Zhao

Authors and Affiliations

  1. Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Yuan-sheng Wan, Xue-jia Zhai, Hong-ai Tan & You-sheng Ai

  2. Beijing Children’s Hospital, Capital Medical University, Beijing, China

    Li-bo Zhao

Authors
  1. Yuan-sheng Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xue-jia Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong-ai Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. You-sheng Ai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li-bo Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to You-sheng Ai or Li-bo Zhao.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wan, Ys., Zhai, Xj., Tan, Ha. et al. Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis. Pharmacogenomics J 21, 200–215 (2021). https://doi.org/10.1038/s41397-020-00197-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-020-00197-2

Search

Advanced search

Quick links